Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

Tolaney, Sara M.Cicin, IrfanBetancourt, RafaelChan, ArleneKaen, DiegoKaufman, Peter A.Delaloge, Suzette2024-06-122024-06-1220200732-183X1527-7755https://hdl.handle.net/20.500.14551/26746Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 29-31, 2020 -- ELECTR NETWORK[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.Conference Object3815Q1WOS:000560368309024